Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton

Ilgen Mender, Serif Senturk, Nuriman Ozgunes, K. Can Akcali, Dimitris Kletsas, Sergei Gryaznov, Alp Can, Jerry W. Shay, Z. Gunnur Dikmen

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Telomerase is a cellular ribonucleoprotein reverse transcriptase that plays a crucial role in telomere maintenance. This enzyme is expressed in approximately 90% of human tumors, but not in the majority of normal somatic cells. Imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'→P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit. In preclinical trials, this compound has been found to inhibit telomerase activity in multiple cancer cell lines, as well as in vivo xenograft mouse models. Currently, GRN163L is being investigated in several clinical trials, including a phase II human non small cell lung cancer clinical trial, in a maintenance setting following standard doublet chemotherapy. In addition to the inhibition of telomerase activity in cancer cell lines, GRN163L causes morphological cell rounding changes, independent of hTR expression or telomere length. This leads to the loss of cell adhesion properties; however, the mechanism underlying this effect is not yet fully understood. In the present study, we observed that GRN163L treatment leads to the loss of adhesion in A549 lung cancer cells, due to decreased E-cadherin expression, leading to the disruption of the cytoskeleton through the alteration of actin, tubulin and intermediate filament organization. Consequently, the less adherent cancer cells initially cease to proliferate and are arrested in the G1 phase of the cell cycle, accompanied by decreased matrix metalloproteinase-2 (MMP-2) expression. These effects of GRN163L are independent of its telomerase catalytic activity and may increase the therapeutic efficacy of GRN163L by decreasing the adhesion, proliferation and metastatic potential of cancer cells in vivo.

Original languageEnglish (US)
Pages (from-to)1709-1715
Number of pages7
JournalInternational journal of oncology
Volume42
Issue number5
DOIs
StatePublished - May 2013

Keywords

  • Cell adhesion
  • E-cadherin
  • GRN163L
  • Matrix metalloproteinase-2
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton'. Together they form a unique fingerprint.

Cite this